Drug intelligence / Profile preview

duopiyin

Development stage: Unknown
Lead developer: Beijing Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Duopiyin (also known as Duopi Yin) is a Traditional Chinese Medicine (TCM) herbal formula developed by the Beijing Hospital of Traditional Chinese Medicine, specifically associated with the teachings of the renowned dermatologist Zhao Bingnan. The formula is primarily composed of various plant peels (pericarps or bark), such as Pericarpium Dictamni, Pericarpium Citri Reticulatae, and Pericarpium Mori, which are traditionally used to dispel wind and resolve dampness to treat skin ailments. It is currently being evaluated in clinical trials for the treatment of chronic refractory urticaria, aiming to provide a therapeutic option for patients who are non-responsive to standard H1-antihistamine treatments.

Other names: Duopi YinDuopi DecoctionZhao Bingnan Duopi Yin

Targets

SYK (Spleen Tyrosine Kinase)

Beyond the preview

Go deeper on duopiyin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on duopiyin.

Explore the full profile